BusinessHemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”By Nasdaq OMXNov 8, 2016, 1:30 PM UTC
BusinessHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine RepublicBy Nasdaq OMXAug 26, 2016, 12:30 AM UTC
